Drug intelligence / Profile preview

ACE1755

Development stage: Preclinical
Lead developer: Acepodia
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ACE1755 is an investigational **CD19-targeted chimeric antigen receptor natural killer cell therapy** being developed by Acepodia for B-cell malignancies such as lymphoma and leukemia. It is an off-the-shelf allogeneic biologic built from Acepodia's proprietary oNK natural killer cell platform and engineered with a CAR directed against CD19 to recognize and kill CD19-expressing malignant B cells. In preclinical lymphoma models, ACE1755 showed antitumor activity and improved survival versus comparator CD19 CAR cord blood-derived NK cells.

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on ACE1755.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACE1755.

Explore the full profile